개인회생 Ozempic maker's new weight loss pill 'available by 2026'
페이지 정보
작성자 COnnor 댓글 0건 조회 11회 작성일 24-04-30 05:17본문
A blockbuster new weight loss pill created by the maker of Ozempic could ready as soon as 2026.
Pharmaceutical titan Novo Nordisk yesterday unveiled promising early results for its experimental drug amycretin that showed patients could lose more than 13 per cent of their weight after just 12 weeks.
Game-changing slimming jab Wegovy, in contrast, is proven to help people lose up to six per cent over the same period.
A phase two drug trial will begin the second half of the year, with results expected in early 2026, the company said.
It means the treatment — which will need to be subject to even larger trials — could be available to consumers shortly after that, pending final regulatory hurdles.
Pharmaceutical titan Novo Nordisk yesterday unveiled promising early results for its experimental drug amycretin that showed patients could lose more than 13 per cent of their weight after just 12 weeks. Game-changing slimming jab Wegovy, in contrast, is proven to help people lose up to six per cent over the same period
Amycretin is similar to Wegovy and sister drug Ozempic.
It targets the same glucagon-like peptide-1 hormone, which regulates appetite and feelings of fullness.
In addition, it stimulates another called amylin which also reduces hunger and Glucoslim kaufen slows stomach emptying.
Results showed the drug also appeared to be safe and well-tolerated among the 16 people who took it over three months, and whose average weight at the start of the trial was 14st (196lbs).
The speed at which people shed pounds on amycretin far outstripped the amount of time it took for Wegovy and Ozempic patients to lose that amount in trials — 68 weeks.
Pharmaceutical titan Novo Nordisk yesterday unveiled promising early results for its experimental drug amycretin that showed patients could lose more than 13 per cent of their weight after just 12 weeks.
Game-changing slimming jab Wegovy, in contrast, is proven to help people lose up to six per cent over the same period.
A phase two drug trial will begin the second half of the year, with results expected in early 2026, the company said.
It means the treatment — which will need to be subject to even larger trials — could be available to consumers shortly after that, pending final regulatory hurdles.
Pharmaceutical titan Novo Nordisk yesterday unveiled promising early results for its experimental drug amycretin that showed patients could lose more than 13 per cent of their weight after just 12 weeks. Game-changing slimming jab Wegovy, in contrast, is proven to help people lose up to six per cent over the same period
Amycretin is similar to Wegovy and sister drug Ozempic.
It targets the same glucagon-like peptide-1 hormone, which regulates appetite and feelings of fullness.
In addition, it stimulates another called amylin which also reduces hunger and Glucoslim kaufen slows stomach emptying.
Results showed the drug also appeared to be safe and well-tolerated among the 16 people who took it over three months, and whose average weight at the start of the trial was 14st (196lbs).
The speed at which people shed pounds on amycretin far outstripped the amount of time it took for Wegovy and Ozempic patients to lose that amount in trials — 68 weeks.
댓글목록
등록된 댓글이 없습니다.